Peter Sykora
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$7.5MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $7.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 23, 2026 | NIH | SBIR Phase II EcoWell: Smart Incubation Technology for Next-Generation Environmental Science Labs | $1.0M | AMELIA TECHNOLOGIES LLC |
| Aug 18, 2025 | NIH | SBIR Phase I Using microsphere technology for the electrochemical measurement of genotoxicity. | $303K | AMELIA TECHNOLOGIES LLC |
| Mar 23, 2024 | NIH | SBIR Phase II EcoWell- A planet in a plate. | $274K | AMELIA TECHNOLOGIES LLC |
| Aug 8, 2023 | NIH | STTR Phase II Development of the UValidate platform for the profiling of topically applied chemical agents. | $864K | AMELIA TECHNOLOGIES LLC |
| Sep 20, 2022 | NIH | STTR Phase II Development of the UValidate platform for the profiling of topically applied chemical agents. | $809K | AMELIA TECHNOLOGIES LLC |
| Sep 20, 2022 | NIH | STTR Phase II Development of the UValidate platform for the profiling of topically applied chemical agents. | $1.7M | AMELIA TECHNOLOGIES LLC with GEORGETOWN UNIVERSITY |
| May 31, 2021 | NIH | STTR Phase I Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers | $51K | AMELIA TECHNOLOGIES LLC |
| Sep 1, 2020 | NIH | SBIR Phase I The development of FastMyco⢠: A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination . | $274K | AMELIA TECHNOLOGIES LLC |
| Jul 29, 2020 | NIH | SBIR Phase I The development of FastMyco⢠: A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination . | $274K | AMELIA TECHNOLOGIES LLC |
| May 1, 2020 | NIH | STTR Phase I Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers | $247K | AMELIA TECHNOLOGIES LLC with GEORGETOWN UNIVERSITY |
| Apr 24, 2020 | NIH | STTR Phase I Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers | $195K | AMELIA TECHNOLOGIES LLC |
| Sep 24, 2019 | NIH | STTR Phase II Expansion of Immuno-CometChip Platform | $8K | AMELIA TECHNOLOGIES LLC |
| Apr 24, 2019 | NIH | STTR Phase II Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing | $827K | AMELIA TECHNOLOGIES LLC |
| May 15, 2018 | NIH | STTR Phase II Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing | $666K | AMELIA TECHNOLOGIES LLC |
Peer ranks
Federal funding#131
Awards as PI#65
Patents#505
Companies
- AMELIA TECHNOLOGIES LLCLinked by awards · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.